pyrazines has been researched along with alpha-chymotrypsin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Streubel, J; von Bruchhausen, F | 1 |
| Aujay, MA; Bennett, MK; Buchholz, TJ; Dajee, M; Demo, SD; Ho, MN; Jiang, J; Kirk, CJ; Laidig, GJ; Lewis, ER; Molineaux, CJ; Parlati, F; Shenk, KD; Smyth, MS; Sun, CM; Vallone, MK; Woo, TM | 1 |
| De Aos, I; Garrett, MW; Huang, S; Kem, DC; Patterson, E; Yu, X | 1 |
| Chen, L; Chen, Z; Gong, S; Guo, L; Lü, S; Wang, J; Yang, J; Zhou, H | 1 |
| Chen, L; Chen, Z; Han, F; Li, J; Lü, S; Wang, J; Xu, X; Yang, J; Zhou, H | 1 |
| Berndt, N; Guida, WC; Kazi, A; Lawrence, H; McLaughlin, ML; Sebti, SM; Springett, GM; Yip, RM | 1 |
| Agyin, JK; Nair, HB; Roy, SS; Santhamma, B; Tekmal, RR | 1 |
| Alarid, ET; Casa, AJ; Ellison-Zelski, SJ; Lee, AV; Powers, GL | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D | 1 |
| Chitambar, CR; Purpi, DP | 1 |
| Bui, TN; Efuet, ET; Keyomarsi, K | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Aujay, M; Azab, AK; Azab, F; Ghobrial, IM; Issa, GC; Liu, Y; Maiso, P; Morgan, B; Ngo, HT; Quang, P; Roccaro, AM; Sacco, A; Zhang, Y | 1 |
| Ambrosio, CE; Araujo, KP; Belizario, JE; Bonuccelli, G; Duarte, CN; Feder, D; Gaiad, TP; Lisanti, MP; Miglino, MA; Moreira, DF | 1 |
| Chen, FT; Yang, CH; Yang, CM | 1 |
| Abramova, EB; Astakhova, TM; Bogomyagkova, YV; Choinzonov, EL; Erokhov, PA; Kondakova, IV; Kuznetsov, NA; Lyupina, YV; Plekhanova, AS; Rodoman, GV; Sharova, NP; Shashova, EE; Slonimskaya, EM; Sumedi, IR | 1 |
| Ahn, YS; Han, SH; Jeong, SJ; Kim, JM; Kim, JS; Shin, JS; Woo, JH | 1 |
| Böhringer, N; Gütschow, M; König, GM; Schäberle, TF | 1 |
1 trial(s) available for pyrazines and alpha-chymotrypsin
| Article | Year |
|---|---|
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
17 other study(ies) available for pyrazines and alpha-chymotrypsin
| Article | Year |
|---|---|
[Effects of amiloride and triamterene on lipolysis and enzyme-induced glucose transport in isolated fat cells].
Topics: Adipose Tissue; Animals; Biological Transport, Active; Chymotrypsin; Dexamethasone; Diuretics; Glucose; Growth Hormone; In Vitro Techniques; Insulin; Lipid Metabolism; Male; Phospholipases; Pyrazines; Rats; Stimulation, Chemical; Triamterene; Trypsin | 1969 |
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chymotrypsin; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Male; Mice; Neoplasm Transplantation; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley | 2007 |
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Catecholamines; Chymotrypsin; Coronary Vessels; Death, Sudden, Cardiac; Dogs; Electrocardiography; Electrophysiology; G-Protein-Coupled Receptor Kinase 3; Heart Ventricles; HSP72 Heat-Shock Proteins; Ligation; Male; Myocardial Infarction; Myocardial Ischemia; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tachycardia; Trypsin | 2008 |
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Survival; Chymotrypsin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; K562 Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2008 |
The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Chymotrypsin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; K562 Cells; Leukemia; Pyrazines | 2010 |
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chymotrypsin; Cyclin-Dependent Kinase Inhibitor p27; Drug Discovery; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neoplasms; Proteasome Inhibitors; Protein Conformation; Pyrazines; Serine Proteinase Inhibitors; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2009 |
BU-32: a novel proteasome inhibitor for breast cancer.
Topics: Animals; Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chymotrypsin; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrazoles; Xenograft Model Antitumor Assays | 2009 |
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Topics: Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Chymotrypsin; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Polymerase II; Signal Transduction | 2010 |
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chymotrypsin; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Mitochondria; NF-kappa B; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Division; Cell Line, Tumor; Chymotrypsin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Organometallic Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrones | 2010 |
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
Topics: Acetylcysteine; Animals; Biological Assay; Boronic Acids; Bortezomib; Cell Extracts; Cells, Cultured; Chymotrypsin; High-Throughput Screening Assays; Inhibitory Concentration 50; Leupeptins; Mice; Models, Biological; Oligopeptides; Ornithine Decarboxylase; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Time Factors | 2011 |
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Chymotrypsin; Coculture Techniques; DNA Fragmentation; Drug Synergism; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma; Mice; Mice, SCID; Oligopeptides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; Serine Proteinase Inhibitors; Unfolded Protein Response; Waldenstrom Macroglobulinemia | 2011 |
Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.
Topics: Animals; Boronic Acids; Bortezomib; Chymotrypsin; Collagen; Dogs; Dystroglycans; Dystrophin-Associated Protein Complex; Gene Expression; Immunohistochemistry; Inflammation; Muscle, Skeletal; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Boronic Acids; Bortezomib; Cell Count; Chymotrypsin; Gene Expression Regulation; Inflammation Mediators; Male; NF-kappa B; Nitric Oxide Synthase Type II; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Retina; Retinal Ganglion Cells; RNA, Messenger | 2013 |
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Topics: Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Chymotrypsin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Proteasome Endopeptidase Complex; Pyrazines; Thyroid Gland; Thyroid Neoplasms | 2013 |
The effect of bortezomib on expression of inflammatory cytokines and survival in a murine sepsis model induced by cecal ligation and puncture.
Topics: Animals; Boronic Acids; Bortezomib; Cecum; Cell Adhesion Molecules; Cell Line; Cell Proliferation; Cell Survival; Chymotrypsin; Cytokines; Disease Models, Animal; Inflammation Mediators; Ligation; Lipopolysaccharides; Lung; Male; Mice, Inbred C57BL; Nitric Oxide; Proteasome Inhibitors; Punctures; Pyrazines; Sepsis | 2015 |
Phileucin - A Cyclic Dipeptide Similar to Phevalin (Aureusimine B) from Streptomyces coelicolor M1146.
Topics: Animals; Cathepsin L; Cattle; Chymotrypsin; Humans; Magnetic Resonance Spectroscopy; Myxococcales; Polyketide Synthases; Protease Inhibitors; Proteinase Inhibitory Proteins, Secretory; Pyrazines; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet; Streptomyces coelicolor; Trypsin Inhibitors | 2017 |